CCRN · Cross Country Healthcare Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.05B | $1.34B | $2.02B | $2.81B | $1.68B | $836.42M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $200.68M | $233.38M | $300.39M | $324.21M | $215.29M | $173.81M |
| Total Operating Expenses | $1.14B | $1.36B | $1.91B | $2.53B | $1.54B | $845.58M |
| D&A | $16.79M | $18.20M | $18.35M | $12.58M | $9.85M | $12.67M |
| Operating Income | ($84.41M) | ($16.86M) | $112.71M | $273.11M | $139.30M | ($9.16M) |
| Interest Expense | $2.22M | $2.19M | $8.09M | $14.39M | $6.87M | $2.89M |
| Income Tax | $11.34M | ($1.84M) | $30.26M | $67.86M | $1.21M | ($188.0K) |
| Net Income | ($94.85M) | ($14.56M) | $72.63M | $188.46M | $132.00M | ($12.96M) |
| EPS - Basic | ($2.93) | ($0.44) | $2.07 | $5.09 | ($0.36) | - |
| EPS - Diluted | ($2.93) | ($0.44) | $2.05 | $5.02 | ($0.36) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $108.74M | $81.63M | $17.09M | $3.60M | $1.04M | $1.60M |
| Accounts Receivable | $167.51M | $223.24M | $372.35M | $641.61M | $493.91M | $170.00M |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $2.04M | $5.74M | $3.04M | $3.14M | - | - |
| Current Assets | $293.59M | $335.00M | $415.15M | $675.67M | $508.27M | $183.11M |
| Total Assets | $448.95M | $589.25M | $679.32M | $947.84M | $732.81M | $356.97M |
| Current Liabilities | $77.76M | $120.40M | $148.59M | $271.64M | $199.77M | $93.42M |
| Long-term Debt | - | - | - | $150.68M | $181.76M | - |
| Total Liabilities | $126.13M | $170.29M | $205.92M | $490.62M | $435.28M | $202.06M |
| Stockholders' Equity | $322.82M | $418.96M | $473.39M | $457.22M | $297.53M | $154.38M |
| Retained Earnings | $123.21M | $218.06M | $238.36M | $165.73M | ($22.73M) | ($154.74M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $48.25M | $120.12M | $248.50M | $134.05M | ($85.62M) | $27.20M |
| Investing Cash Flow | ($8.16M) | ($8.71M) | ($13.78M) | ($43.87M) | ($34.05M) | ($4.62M) |
| Financing Cash Flow | ($13.01M) | ($46.85M) | ($221.24M) | ($87.60M) | $119.09M | ($22.01M) |
| CapEx | $8.16M | $8.71M | $13.97M | $8.79M | $7.17M | $4.62M |
| Free Cash Flow | $40.09M | $111.40M | $234.52M | $125.26M | ($92.79M) | $22.59M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -8.0% | -1.3% | 5.6% | 9.7% | 8.3% | -1.1% |
| EBITDA margin | -6.4% | 0.1% | 6.5% | 10.2% | 8.9% | 0.4% |
| Net margin | -9.0% | -1.1% | 3.6% | 6.7% | 7.9% | -1.5% |
| Free cash flow margin | 3.8% | 8.3% | 11.6% | 4.5% | -5.5% | 2.7% |
| FCF / Net income | -0.42 | -7.65 | 3.23 | 0.66 | -0.70 | -1.74 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 19.0% | 17.4% | 14.9% | 11.6% | 12.8% | 20.8% |
| Effective tax rate | - | - | 29.4% | 26.5% | 0.9% | - |
| Return on assets | -21.1% | -2.5% | 10.7% | 19.9% | 18.0% | -3.6% |
| Return on equity | -29.4% | -3.5% | 15.3% | 41.2% | 44.4% | -8.4% |
| Return on invested capital | - | - | - | 33.0% | 28.8% | - |
| Liquidity | ||||||
| Current ratio | 3.78 | 2.78 | 2.79 | 2.49 | 2.54 | 1.96 |
| Quick ratio | 3.78 | 2.78 | 2.79 | 2.49 | 2.54 | 1.96 |
| Cash ratio | 1.40 | 0.68 | 0.12 | 0.01 | 0.01 | 0.02 |
| Leverage | ||||||
| Debt / Equity | - | - | - | 0.33 | 0.61 | - |
| Debt / Assets | - | - | - | 0.16 | 0.25 | - |
| Debt / EBITDA | - | - | - | 0.53 | 1.22 | - |
| Interest coverage | -38.1x | -7.7x | 13.9x | 19.0x | 20.3x | -3.2x |
| Equity multiplier | 1.39 | 1.41 | 1.43 | 2.07 | 2.46 | 2.31 |
| Liabilities / Assets | 0.28 | 0.29 | 0.30 | 0.52 | 0.59 | 0.57 |
| Efficiency | ||||||
| Asset turnover | 2.35 | 2.28 | 2.97 | 2.96 | 2.29 | 2.34 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 58d | 61d | 67d | 83d | 108d | 74d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | 11.0x | 5.3x | - | - |
| P / B | 0.8x | 1.4x | 1.7x | 2.2x | 3.5x | 2.1x |
| P / S | 0.2x | 0.5x | 0.4x | 0.4x | 0.6x | 0.4x |
| EV / EBITDA | - | 392.9x | 6.0x | 4.0x | 8.2x | 90.7x |
| Growth | ||||||
| Revenue growth (YoY) | -21.6% | -33.5% | -28.0% | 67.4% | 100.5% | 1.7% |
| Revenue CAGR (3y) | -27.8% | -7.1% | 34.2% | 50.6% | 26.2% | - |
| Revenue CAGR (5y) | 4.7% | 10.3% | 19.4% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -400.5% | - | -58.7% | 96.1% | - | 41.7% |
| Net income growth (YoY) | -551.6% | - | -61.5% | 42.8% | - | 77.5% |
| EPS growth (YoY) | -565.9% | - | -59.2% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | 37.8% | - | - |
| FCF growth (YoY) | -64.0% | -52.5% | 87.2% | - | - | 768.1% |
| FCF CAGR (5y) | 12.2% | 112.0% | 70.2% | 25.4% | - | 7.3% |
| Book value growth (YoY) | -22.9% | -11.5% | 3.5% | 53.7% | 92.7% | -5.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$1.05B totalNurse And Allied Staffing$862.78M · 81.8%
Physician Staffing$191.51M · 18.2%
Product / service
$862.78M totalTemporary Staffing Services$841.78M · 97.6%
Other Services$21.00M · 2.4%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
3.41
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Help Supply Services
Comparing CROSS COUNTRY HEALTHCARE INC against the 5 most active filers in the same SIC group.